ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Creative Diagnostics Launches Comprehensive Host Cell DNA Assay Kits for Bioprocess Impurity Analysis

Creative Diagnostics Launches Comprehensive Host Cell DNA Assay Kits for Bioprocess Impurity Analysis
Creative Diagnostics is pleased to announce the launch of its comprehensive suite of Host Cell DNA Assay Kits.

Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, is pleased to announce the launch of its comprehensive suite of Host Cell DNA Assay Kits. These innovative kits empower researchers and manufacturers to effectively detect and quantify residual host cell DNA impurities in biological products, ensuring product safety and regulatory compliance throughout the biopharmaceutical manufacturing process.

The detection of residual host cell DNA throughout the biopharmaceutical manufacturing process is an important step in ensuring product safety and batch validation. As an expert in bioprocess impurity analysis, Creative Diagnostics offers host cell DNA assay kits for the detection of host cell DNA impurities in specific recombinant expression systems in biologic products, targeting mammalian, yeast, bacterial, viral, insect cells and more. These products can be used in biological agent development to provide researchers with host cell DNA information to guide bioprocess optimization and reduce host cell DNA levels.

Creative Diagnostics provides host cell DNA assay kits for specific cell line expression systems based on the qPCR technique, which can be used to rapidly detect residual host cell DNA contamination in biologics at any stage of product development. Biological products (e.g., recombinant proteins, antibodies, and vaccines) are expressed from host cells such as bacteria, yeast, animal cells and continuous cell lines during the production process. Even after a rigorous purification process, the products still contain fragments of DNA from the host cells.

In addition, Creative Diagnostics assay kits provide highly sensitive and accurate detection and quantification of host cell DNA impurities. The residual DNA molecules present in the human body with biological products can lead to an increased risk of carcinogenesis, infection and immunomodulation. The WHO and the European Union allow residual DNA levels of up to 10 ng/dose, and the US FDA allows such levels of up to 100 pg/dose. To meet these requirements, highly sensitive and accurate methods are needed to detect and quantify low levels of DNA.

For example, the E. coli DNA Residue Assay Kit (Cat. No. DDNA-021) is based on the principle of the PCR fluorescent probe method for the quantitative detection of E. coli DNA residues in samples, which is fast, specific and reliable, with the lowest detection limit of fg level. The kit is supplied with a reference standard for the quantification of E. coli DNA, and can be used in conjunction with the Creative Diagnostics Host Cell DNA Prep Kit to accurately determine the amount of residual E. coli DNA in biological samples.

Creative Diagnostics' host cell DNA assay kits are designed to detect impurities in recombinant expression systems and include a wide range of required assays. The company also offers program-specific host cell DNA assay kit development services. For more information, please visit https://qbd.creative-diagnostics.com/products/host-cell-dna-assay-kits.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
State: New York
Country: United States
Website: https://qbd.creative-diagnostics.com/


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.